The drugmaker said the recall of cefdinir for oral suspension was due to a report of a metal piece found in the product bottle.
The FDA has classified the recall as a Class 2, which is issued when the use or exposure to the drug may cause adverse events.
Cefdinir for oral suspension is manufactured by Lupin’s manufacturing facility in central India. The affected lot is F802335 and is packaged in 60-milliliter bottles.
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
